David E. Light

Statistics

Publications

Citations

174

H-Index

Active since

2018

Affiliations

Flatiron Health (United States)(Current)

United States Food and Drug Administration

David E. Light is an author at Flatiron Health (United States) specializing in cancer immunotherapy, cancer pharmacology, and programmed cell death protein 1 (pd-1) pathway.

Publications per year

2018–2018

Publications

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

Sean Khozin, Amy P. Abernethy, Nathan C. Nussbaum et al. · The Oncologist · 2018 · 98 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Sean Khozin, Kenneth R. Carson, Jizu Zhi et al. · The Oncologist · 2018 · 76 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–2 of 2